SciSparc announces results from preclinical trial of PEA with Clearmind’s MEAI

SciSparc announced earlier this week results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem. The trial was conducted as part of the collaboration between SciSparc and Clearmind Medicine. The combination treatment includes palmitoylethanolamide, an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression. The goal of the trial was to identify the optimal dosage for the Combination Treatment and, in turn, observe the safety and impact thereof on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Fourteen different treatment groups were created receiving single treatment doses ranging from 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. MEAI administration exhibited a meaningful degree of tolerance, leaving the animals’ viability unaffected across all experimental groups. Similar results were also observed in groups treated by the Combination Treatment, with the most prominent effects observed when combining MEAI and PEA, particularly at 20 and 10 mg/kg. Results indicated: The administered treatment exhibited a meaningful degree of tolerance, leaving the viability of the mice unaffected across all experimental groups. Combining MEAI and PEA, particularly at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. The changed rates of oxygen consumption and carbon dioxide emission indicate increases in the metabolic process and fat burn. A notable reduction in food consumption and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted particularly at 20 and 10 mg/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity.